SynthesisWorld journal of surgical oncology2026
Prognostic and clinicopathological significance of heat shock proteins in colorectal cancer patients: a meta-analysis.
Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe impact of heat shock proteins (HSPs) expression levels on the prognosis of patients with colorectal cancer (CRC) remains controversial. Therefore, we conducted a meta-analysis to evaluate the prognostic significance of HSPs expression in CRC patients and its relationship with clinical pathological features.
methodsWe searched for eligible studies from PubMed, Embase, Cochrane, and Web of Science databases, and extracted the hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), relapse-free survival (RFS), or cancer-specific survival (CSS), along with their clinical pathological characteristics. Meta-analysis was performed using either a fixed-effects model or a random-effects model, depending on the heterogeneity between studies.
resultsA total of 20 studies, including 3919 CRC patients, were included in this meta-analysis. The results showed that high expression of HSPs can predict poor OS in CRC patients (HR = 1.79, 95% CI: 1.39–2.30, P < 0.00001). Subgroup analyses revealed that high expression of HSP70 (HR = 1.75, 95% CI: 1.10–2.78, P = 0.02), HSP27 (HR = 1.73, 95% CI: 1.34–2.25, P < 0.0001), and HSP47 (HR = 2.91, 95% CI: 1.39–6.08, P = 0.005) were associated with increased risk for poorer OS, but the expression of HSP90 (HR = 1.28, 95% CI: 0.60–2.72, P = 0.52) was not significantly correlated with OS in CRC patients. Moreover, high expression of HSPs may predict poor DFS (HR = 1.56, 95% CI: 1.18–2.06, P = 0.002), RFS (HR = 2.15, 95% CI: 1.37–3.38, P = 0.0008), and CSS (HR = 1.65, 95% CI: 1.07–2.42, P = 0.0003) in CRC patients. In addition, high expression of HSPs was significantly correlated with high TNM stage (OR = 1.29, 95% CI: 1.01–1.65, P = 0.04).
conclusionThese findings indicate that high expression of HSP70, HSP27, and HSP47 may have a significant adverse effect on the prognosis of CRC patients, and contribute to the prognosis evaluation of these patients and potentially guide the development of targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.